Table 1. Characteristics of interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) participants, Washington University School of Medicine and the University of Alabama at Birmingham, 2010-2013.
| All (n=76) | Female (n=46) | Male (n=30) | p-value1 | |
|---|---|---|---|---|
| Baseline age (years, mean (range)) | 47.7 (18.9 -80.0) | 46.6 (18.9 - 75.8) | 49.4 (26.6 - 80.0) | 0.45 |
| Caucasian (%) | 88.2 | 89.1 | 86.7 | 0.73 |
| Met IC/BPS criteria at baseline (%)2 | 94.7 | 100.0 | 86.7 | 0.02 |
| Duration of symptoms at baseline (years, mean (range)) | 13.3 (0.2 - 54.2) | 16.4 (0.2 - 52.0) | 8.6 (0.9 - 54.2) | 0.01 |
| Non-flare symptom levels (mean (range)): | ||||
| Pelvic pain, pressure, or discomfort in the past two weeks (on a scale of 0-10) | 4.2 (0.0 - 10.0) | 4.9 (0.0 - 10.0) | 3.2 (0.0 - 9.0) | 0.007 |
| Urgency in the past two weeks (on a scale of 0-10) | 3.9 (0.0 - 10.0) | 4.8 (0.0 - 10.0) | 2.6 (0.0 - 8.0) | 0.001 |
| Frequency in the past two weeks (on a scale of 0-10) | 4.0 (0.0 - 10.0) | 4.9 (0.0 - 10.0) | 2.7 (0.0 - 9.0) | 0.002 |
| Genitourinary pain index (on a scale of 0-23) | 10.5 (0.0 - 22.0) | 11.6 (0.0 - 22.0) | 9.0 (0.0 - 20.0) | 0.06 |
| Interstitial cystitis symptom index (on a scale of 0-20) | 8.7 (0.0 - 18.0) | 10.4 (3.0 - 18.0) | 6.4 (0.0 - 16.0) | 0.0002 |
| Interstitial cystitis problem index (on a scale of 0-16) | 7.0 (0.0 - 16.0) | 8.8 (1.0 - 16.0) | 4.8 (0.0 - 14.0) | 0.0002 |
| Flare at baseline (%) | 33.0 | 35.6 | 30.0 | 0.62 |
| Presence of non-urological associated syndromes (%):3 | ||||
| Irritable bowel syndrome | 26.8 | 28.6 | 24.1 | 0.68 |
| Fibromyalgia | 9.9 | 14.3 | 3.5 | 0.23 |
| Chronic fatigue syndrome | 12.7 | 19.1 | 3.5 | 0.07 |
| Any associated syndrome | 38.0 | 45.2 | 27.6 | 0.13 |
P-values were calculated by Student's t-tests or chi-squared tests, as appropriate.
Defined as an unpleasant sensation of pain, pressure, or discomfort perceived to be related to the bladder/prostate and/or pelvic region, associated with lower urinary tract symptoms, for the majority of time in the three months before baseline.
Assessed by the Complex Medical Symptoms Inventory[15]